Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

677 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy.
Amamoto R, Yagi M, Song Y, Oda Y, Tsuneyoshi M, Naito S, Yokomizo A, Kuroiwa K, Tokunaga S, Kato S, Hiura H, Samori T, Kang D, Uchiumi T. Amamoto R, et al. Among authors: tokunaga s. Cancer Sci. 2011 Mar;102(3):639-47. doi: 10.1111/j.1349-7006.2010.01828.x. Epub 2011 Jan 23. Cancer Sci. 2011. PMID: 21205079 Free article.
Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm.
Miyasaka Y, Ohtsuka T, Tamura K, Mori Y, Shindo K, Yamada D, Takahata S, Ishigami K, Ito T, Tokunaga S, Oda Y, Mizumoto K, Nakamura M, Tanaka M. Miyasaka Y, et al. Among authors: tokunaga s. Ann Surg. 2016 Jun;263(6):1180-7. doi: 10.1097/SLA.0000000000001368. Ann Surg. 2016. PMID: 26334637
Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml.
Ito K, Yokomizo A, Tokunaga S, Arai G, Sugimoto M, Akakura K, Hasumi H, Sakai H, Ouraji A, Oki R, Kashiwagi E, Kobori Y, Hirama H, Kitoh H, Uemura H, Hakariya T, Suzuki K; Members of PROPHET. Ito K, et al. Among authors: tokunaga s. J Urol. 2020 Jan;203(1):83-91. doi: 10.1097/JU.0000000000000495. Epub 2019 Aug 20. J Urol. 2020. PMID: 31430244
Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study.
Yano T, Yamazaki K, Maruyama R, Tokunaga S, Shoji F, Higashi H, Takeo S, Ichinose Y, Maehara Y; Lung Oncology Group in Kyushu (LOGIK). Yano T, et al. Among authors: tokunaga s. Lung Cancer. 2010 Feb;67(2):184-7. doi: 10.1016/j.lungcan.2009.03.028. Epub 2009 May 5. Lung Cancer. 2010. PMID: 19409643 Clinical Trial.
677 results